TORONTO, April 23, 2012 /CNW Telbec/ - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY) has invested $1.3 million in a "condensing economizer." The cutting-edge equipment, which is the size of a small building, converts waste heat into energy. The investment was part of Sanofi Pasteur's ongoing commitment to reducing its environmental impact and promises to reduce the site's carbon dioxide emissions by more than 2,300 tonnes per year.
Mark Lievonen, President of Sanofi Pasteur Limited, says "these results make the installation well worth it. We're proud of Sanofi Pasteur's commitment to preventing pollution, protecting the environment, and conserving energy and natural resources in order to achieve sustainable development for the benefit of current and future generations."
Enbridge Gas Distribution, Canada's largest natural gas distribution utility, conducted a complete assessment of Sanofi Pasteur's boiler plant performance in March 2011 and presented energy savings recommendations to Sanofi Pasteur's Energy Task Force in Toronto.
"Enbridge was proud to help Sanofi Pasteur identify opportunities for significant energy efficiency measures in its operations," said Andrew Mandyam who manages energy efficiency programs at Enbridge Gas Distribution. "Through its leadership, Sanofi Pasteur is proving that energy efficiency measures can make not only environmental sense, but business sense by saving money as well."
Through Enbridge's energy efficiency Industrial Demand Side Management Program, Sanofi Pasteur received a financial incentive grant of $200,000 toward the implementation of this efficiency measure.
"As a manufacturing site, we have a responsibility to look at every opportunity we have to conserve energy. By working with Enbridge Gas Distribution and installing the condensing economizer, we were able to make a significant dent in our energy consumption," said Melanee Short, Sanofi Pasteur's Deputy Director, Environment and Sustainability, responsible for environmental initiatives.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect
to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates", "plans"
and similar expressions. Although Sanofi's management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking information
and statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of
Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including
post marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities, trends
in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number
of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those
listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2011. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Image with caption: "From left to right: Peter Goldman, Enbridge Gas Distribution; Anand Krishnan, Enbridge Gas Distribution; Mark Lievonen, Sanofi Pasteur Limited; Paul Green, Enbridge Gas Distribution; Paul Alves, Sanofi Pasteur; James Morfea, Sanofi Pasteur; Paula Casalino, Facilities Management (CNW Group/SANOFI PASTEUR)". Image available at: http://photos.newswire.ca/images/download/20120423_C7874_PHOTO_EN_12588.jpg
Canadian Media Relations
Nancy Simpson
T. 416-667-2955
Nancy.simpson@sanofipasteur.com
www.sanofipasteur.ca